NASDAQ:OM

Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Technology, Medical Devices, FDA, Health Technology, Professional Services, Software, Health, Data Analytics, General Health, Growth, Medicine, Mental, Business, Patient, Stryker Corporation, Gold, Business development, Acquisition, University, Marketing, 3Com, Fortune 500, Dialysis, Movement, Audit committee, Management

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its board of directors.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its board of directors.
  • “Brent brings a wealth of healthcare expertise to the Outset board, including in growing and scaling software-enabled business models, which is well-aligned with our recurring revenue model,” said Leslie Trigg, Chair and Chief Executive Officer.
  • “As we welcome Brent, we want to also thank Katie for her service to the Outset board during a period of growth and change following our public offering,” added Ms. Trigg.
  • “We wish her well as she begins an exciting new phase of her career journey.”
    Mr. Lang will serve on the Audit Committee of the Outset board.

Outset Medical to Present at the 44th Annual TD Cowen Health Care Conference

Retrieved on: 
Monday, February 26, 2024
Diabetes, Health, Medical Devices, Dialysis, Medicine

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 44th annual TD Cowen Health Care conference on Tuesday, March 5, 2024, at 1:30 p.m. Eastern time.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 44th annual TD Cowen Health Care conference on Tuesday, March 5, 2024, at 1:30 p.m. Eastern time.

Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024
Diabetes, Health Technology, Health, Medical Devices, Medicine, Investment, Marketing, Dialysis, Growth, S&M, GAAP, Webcast, Patient, G&A, Appendix, Bank statement, Research, Video game

Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Fourth quarter gross margin reached 25.3% (26.7% on a non-GAAP basis) compared to 16.5% (17.1% on a non-GAAP basis) in the fourth quarter of 2022.
  • Product revenue was $22.9 million, representing a decrease of 13.2% compared to $26.4 million in the fourth quarter of 2022.
  • Product gross profit was $8.3 million, compared to $4.3 million of product gross profit in the fourth quarter of 2022.

Outset Medical to Report Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, February 21, 2024

Retrieved on: 
Monday, February 5, 2024
Diabetes, Health Technology, Health, Medical Devices, Medicine, Dialysis

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2023 after the close of trading on Wednesday, February 21, 2024.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2023 after the close of trading on Wednesday, February 21, 2024.
  • On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results.
  • The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, February 21, 2024.
  • A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/ .

Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and Non-GAAP Gross Margin Guidance

Retrieved on: 
Monday, January 8, 2024
Health Technology, Health, Other Health, Medical Devices, Medicine, Growth, Investment, Patient, Dialysis, ICU, Video game

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023, and provided 2024 financial guidance.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023, and provided 2024 financial guidance.
  • Unaudited Fourth Quarter and Year End Results, and Recent Highlights
    Revenue in the fourth quarter totaled $30.5 million, bringing revenue for 2023 to $130 million, a 13% increase compared to $115 million in 2022.
  • Consumable revenue grew nearly 50% year-over-year driven by strong utilization of Tablo consoles in the acute and home settings, and contributing to recurring revenue of more than 50% of total revenue in 2023.
  • Non-GAAP gross margin is expected to expand to the low-30% range for the full year 2024 and exit the year in the mid-30% range for the fourth quarter of 2024.

Outset Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
FDA, Health Technology, Health, Medical Devices, Medicine, Dialysis

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 42nd annual J.P. Morgan Healthcare conference on Monday, January 8, 2024, at 5:15 p.m. Pacific time.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 42nd annual J.P. Morgan Healthcare conference on Monday, January 8, 2024, at 5:15 p.m. Pacific time.

Outset Medical (OM) Investigated for Possible Securities Law Violations: Hagens Berman, National Trial Attorneys, Encourages Investors with Losses to Contact the Firm’s Attorneys

Retrieved on: 
Thursday, November 16, 2023
SAN, Person, Letter, Dialysis, FDA, Hagens Berman, Life insurance, Medical device, Pharmaceutical industry, Outset Contemporary Art Fund

SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Outset Medical, Inc. (NASDAQ: OM) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Outset Medical, Inc. (NASDAQ: OM) investors who suffered substantial losses to submit your losses now .
  • In late July 2022, Outset disclosed the FDA cleared the 510(k) application of Tablo for patient use in the home.
  • More recently, on Oct. 12, 2023, Outset Medical reported disappointing preliminary Q3 2023 revenues and slashed its FY 2023 revenue guidance.
  • “We’re focused on investors’ losses and investigating whether Outset may have misled investors about Tablo’s near-term prospects,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM

Retrieved on: 
Monday, November 13, 2023
Chronic kidney disease, LLP, Letter, FDA, Marketing, Hemofiltration, Health, Diabetes, News, Novo Nordisk, Pomerantz, CRRT

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Outset and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Outset Medical to Present at BofA Home Care Conference

Retrieved on: 
Wednesday, November 29, 2023
Biotechnology, Health Technology, Health, Medical Devices, Kidney disease, Bank of America, Conference, Medicine, MD, Dialysis, Medical device

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a virtual panel discussion at the BofA Securities Home Care Conference on Monday, December 4, 2023, at 12:00pm PT / 3:00pm ET.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a virtual panel discussion at the BofA Securities Home Care Conference on Monday, December 4, 2023, at 12:00pm PT / 3:00pm ET.
  • The panel discussion will include Leslie Trigg, Outset’s Chair and Chief Executive Officer, Michael Aragon, MD, Outset’s Chief Medical Officer, a home healthcare provider, and a patient currently dialyzing at home with the Tablo® Hemodialysis System.
  • The discussion will focus on home hemodialysis and managing end-stage renal disease.

Outset Medical to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health Technology, Health, Medical Devices, Conference, Medicine, Dialysis, Pharmaceutical industry

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in fireside chats at two upcoming investor conferences.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in fireside chats at two upcoming investor conferences.
  • Outset will participate in the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023, and the Jefferies London Healthcare Conference on Thursday, November 16, 2023.